Synthesis And Biological Activity Of Isoxazole Biaryl Compound

Arylisoxazole compounds have antibacterial,anti-inflammatory,antioxidant,antiviral,and anti-tumor biological activities,and are widely used in organic chemistry,agricultural pharmacy,and pharmaceutical chemistry.In recent years,researches on the synthesis and biological activity of these compounds have aroused extensive research interest.Based on the excellent biological activities of arylisoxazole compounds,this thesis intends to develop a synthesis method for these compounds using microwave synthesis technology,and further study their antibacterial and anti-tumor biological activities.In the context of the rapid development of green chemistry,we have successfully developed a new method for the synthesis of arylisoxazole compounds with the help of microwave technique in green chemistry.This reaction was completed through[3+2]cycloaddition reaction using a one-pot method.This strategy performed the characteristics of fast,economical,green,and wide application range of functional groups.Subsequently,we constructed a library of arylisoxazole compounds with novel structures,and screened the antibacterial activities of thirty-five compounds with turbidimetry.The experimental results showed that 4-nitro-3-phenylisoxazoles had good antibacterial activity,and the antibacterial activity of nine compounds in this series against Xanthomonas oryzae pv.oryzae（Xoo）,Xanthomonas axonopodsis pv.citri（Xac）,and Pseudomonas syingae pv.actinidiae（Psa）was much higher than the listed pesticide Bismerthiazol.Finally,we designed and synthesized a series of novel arylisoxazole compounds containing3,5-disubstituted rhodanine fragments in the fragment hybridization strategy.The antitumor activity of total twenty-three compounds against human lung cancer cell line A549 was screened with MTT method.The experimental results showed that some compounds exhibited well antitumor activity.Especially,the best compound（E）-N-（3-（4 bromophenyl）isoxazol-4-yl）acryloyl)-N-thioformylglycine ethyl ester had an IC₅₀ value of 6.34μM against A549 cells.It was superior to the listed lung cancer treatment drug Gefitinib.